300 related articles for article (PubMed ID: 30967527)
1. Bortezomib-inducible long non-coding RNA myocardial infarction associated transcript is an oncogene in multiple myeloma that suppresses miR-29b.
Fu Y; Liu X; Zhang F; Jiang S; Liu J; Luo Y
Cell Death Dis; 2019 Apr; 10(4):319. PubMed ID: 30967527
[TBL] [Abstract][Full Text] [Related]
2. Lnc NEAT1/miR-29b-3p/Sp1 form a positive feedback loop and modulate bortezomib resistance in human multiple myeloma cells.
Che F; Ye X; Wang Y; Ma S; Wang X
Eur J Pharmacol; 2021 Jan; 891():173752. PubMed ID: 33253679
[TBL] [Abstract][Full Text] [Related]
3. LncRNA H19 overexpression induces bortezomib resistance in multiple myeloma by targeting MCL-1 via miR-29b-3p.
Pan Y; Zhang Y; Liu W; Huang Y; Shen X; Jing R; Pu J; Wang X; Ju S; Cong H; Chen H
Cell Death Dis; 2019 Feb; 10(2):106. PubMed ID: 30728351
[TBL] [Abstract][Full Text] [Related]
4. Exosomal mRNAs and lncRNAs involved in multiple myeloma resistance to bortezomib.
Tang JX; Chen Q; Li Q; He YH; Xiao D
Cell Biol Int; 2021 May; 45(5):965-975. PubMed ID: 33372728
[TBL] [Abstract][Full Text] [Related]
5. LncRNA PRAL is closely related to clinical prognosis of multiple myeloma and the bortezomib sensitivity.
Xiao G; Li Y; Wang Y; Zhao B; Zou Z; Hou S; Jia X; Liu X; Yao Y; Wan J; Xiong H
Exp Cell Res; 2018 Sep; 370(2):254-263. PubMed ID: 29944867
[TBL] [Abstract][Full Text] [Related]
6. CircRNA ITCH increases bortezomib sensitivity through regulating the miR-615-3p/PRKCD axis in multiple myeloma.
Liu J; Du F; Chen C; Li D; Chen Y; Xiao X; Hou X
Life Sci; 2020 Dec; 262():118506. PubMed ID: 33031827
[TBL] [Abstract][Full Text] [Related]
7. Dysregulation of LncRNA ANRIL mediated by miR-411-3p inhibits the malignant proliferation and tumor stem cell like property of multiple myeloma via hypoxia-inducible factor 1α.
Wang M; Zhao HY; Zhang JL; Wan DM; Li YM; Jiang ZX
Exp Cell Res; 2020 Nov; 396(1):112280. PubMed ID: 32961145
[TBL] [Abstract][Full Text] [Related]
8. hsa-miR-631 resensitizes bortezomib-resistant multiple myeloma cell lines by inhibiting UbcH10.
Xi H; Li L; Du J; An R; Fan R; Lu J; Wu YX; Wu SX; Hou J; Zhao LM
Oncol Rep; 2017 Feb; 37(2):961-968. PubMed ID: 28000886
[TBL] [Abstract][Full Text] [Related]
9. Long non-coding RNA ANGPTL1-3 promotes multiple myeloma bortezomib resistance by sponging miR-30a-3p to activate c-Maf expression.
Nian F; Zhu J; Chang H
Biochem Biophys Res Commun; 2019 Jul; 514(4):1140-1146. PubMed ID: 31103265
[TBL] [Abstract][Full Text] [Related]
10. Myocardial infarction associated transcript (MIAT) promotes papillary thyroid cancer progression via sponging miR-212.
Wang R; Zhao L; Ji L; Bai L; Wen Q
Biomed Pharmacother; 2019 Oct; 118():109298. PubMed ID: 31404776
[TBL] [Abstract][Full Text] [Related]
11. Enhanced antitumor effect of combination of annexin A1 knockdown and bortezomib treatment in multiple myeloma in vitro and in vivo.
Jia C; Kong D; Guo Y; Li L; Quan L
Biochem Biophys Res Commun; 2018 Nov; 505(3):720-725. PubMed ID: 30292410
[TBL] [Abstract][Full Text] [Related]
12. STMN1 promotes cell malignancy and bortezomib resistance of multiple myeloma cell lines via PI3K/AKT signaling.
Wang L; Cao J; Tao J; Liang Y
Expert Opin Drug Saf; 2024 Mar; 23(3):277-286. PubMed ID: 37642368
[TBL] [Abstract][Full Text] [Related]
13. Hyaluronic acid shell and disulfide-crosslinked core micelles for in vivo targeted delivery of bortezomib for the treatment of multiple myeloma.
Gu Z; Wang X; Cheng R; Cheng L; Zhong Z
Acta Biomater; 2018 Oct; 80():288-295. PubMed ID: 30240956
[TBL] [Abstract][Full Text] [Related]
14. BDNF/TrkB confers bortezomib resistance in multiple myeloma by inducing BRINP3.
Bao L; Wang Y; Lu M; Shi L; Chu B; Gao S
Biochim Biophys Acta Gen Subj; 2023 Mar; 1867(3):130299. PubMed ID: 36565997
[TBL] [Abstract][Full Text] [Related]
15. ZHX2 mediates proteasome inhibitor resistance via regulating nuclear translocation of NF-κB in multiple myeloma.
Jiang J; Sun Y; Xu J; Xu T; Xu Z; Liu P
Cancer Med; 2020 Oct; 9(19):7244-7252. PubMed ID: 32780537
[TBL] [Abstract][Full Text] [Related]
16. Blockade of deubiquitinase USP7 overcomes bortezomib resistance by suppressing NF-κB signaling pathway in multiple myeloma.
Yao Y; Zhang Y; Shi M; Sun Y; Chen C; Niu M; Zhang Q; Zeng L; Yao R; Li H; Yang J; Li Z; Xu K
J Leukoc Biol; 2018 Dec; 104(6):1105-1115. PubMed ID: 30024656
[TBL] [Abstract][Full Text] [Related]
17. lncRNA MIAT promotes proliferation and invasion of HCC cells via sponging miR-214.
Huang X; Gao Y; Qin J; Lu S
Am J Physiol Gastrointest Liver Physiol; 2018 May; 314(5):G559-G565. PubMed ID: 29097358
[TBL] [Abstract][Full Text] [Related]
18. Rs1894720 polymorphism in MIAT increased susceptibility to age-related hearing loss by modulating the activation of miR-29b/SIRT1/PGC-1α signaling.
Hao S; Wang L; Zhao K; Zhu X; Ye F
J Cell Biochem; 2019 Apr; 120(4):4975-4986. PubMed ID: 30556210
[TBL] [Abstract][Full Text] [Related]
19. Upregulated expression and function of the α4β1 integrin in multiple myeloma cells resistant to bortezomib.
Sevilla-Movilla S; Arellano-Sánchez N; Martínez-Moreno M; Gajate C; Sánchez-Vencells A; Valcárcel LV; Agirre X; Valeri A; Martínez-López J; Prósper F; Mollinedo F; Teixidó J
J Pathol; 2020 Sep; 252(1):29-40. PubMed ID: 32501543
[TBL] [Abstract][Full Text] [Related]
20. MiR-29b replacement inhibits proteasomes and disrupts aggresome+autophagosome formation to enhance the antimyeloma benefit of bortezomib.
Jagannathan S; Vad N; Vallabhapurapu S; Vallabhapurapu S; Anderson KC; Driscoll JJ
Leukemia; 2015 Mar; 29(3):727-38. PubMed ID: 25234165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]